Lv61
2040 积分 2024-12-14 加入
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
10天前
已完结
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
13天前
已完结
Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation
14天前
已完结
The resurgence of covalent drugs
15天前
已完结
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
15天前
已完结
Metabolite identification of a new tyrosine kinase inhibitor, HM781‐36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry
15天前
已完结
A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models
1个月前
已完结
Targeting thymine DNA glycosylase induces synthetic lethality in p53-deficient cancers
1个月前
已完结
Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia
2个月前
已完结
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
3个月前
已完结
皖公网安备34019202002308
